Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
11:55:00 2026-09-08 am EDT
|
5-day change | 1st Jan Change | ||
| 71.20 EUR | -0.56% |
|
-0.50% | +14.10% |
| Sep. 08 | Eurofins Scientific Downgraded by Morgan Stanley |  |
| Aug. 24 | Wall Street's Three-Way Stress Test | |
| Market Cap | 12.36B 14.38B 11.63B 10.61B 19.8B 1,363B 19.91B 138B 53.31B 697B 53.98B 52.8B 2,217B | P/E 2026 * |
23.7x | P/E 2027 * | 18.8x |
|---|---|---|---|---|---|
| Enterprise Value | 15.73B 18.29B 14.8B 13.5B 25.2B 1,734B 25.33B 175B 67.82B 886B 68.68B 67.18B 2,820B | EV / Sales 2026 * |
2.07x | EV / Sales 2027 * | 1.92x |
| Free-Float |
60.39% | Yield 2026 * |
1.13% | Yield 2027 * | 1.28% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
London S.E.
| 0MV5 | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
CBOE
| 0MV5 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript : Eurofins Scientific SE
| 1 day | -0.56% | ||
| 1 week | -0.50% | ||
| Current month | -1.85% | ||
| 1 month | +2.01% | ||
| 3 months | +9.74% | ||
| 6 months | +10.25% | ||
| Current year | +14.10% |
| 1 week | 68.38 |  | 74.78 |
| 1 month | 68.38 | | 74.78 |
| Current year | 56.84 | | 74.78 |
| 1 year | 54.86 | | 74.78 |
| 3 years | 39.47 | | 74.78 |
| 5 years | 39.47 | | 127.68 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.56% | -0.50% | +11.39% | +31.41% | 14.45B | |
| -0.82% | -3.77% | -2.49% | +14.92% | 48.41B | |
| -1.29% | -1.22% | +404.92% | +545.45% | 45.01B | |
| -3.20% | +0.33% | +38.11% | +21.39% | 44.07B | |
| -1.89% | -2.00% | +1.45% | +82.46% | 40.73B | |
| -1.72% | -2.61% | +13.09% | +42.33% | 33.21B | |
| -0.17% | +3.78% | - | - | 17.77B | |
| -0.07% | +1.32% | +20.08% | +117.95% | 16.5B | |
| -2.68% | -0.56% | +73.31% | +40.56% | 13.77B | |
| -3.95% | -1.90% | -10.95% | -36.70% | 12.72B | |
| Average | -1.64% | -0.42% | +60.99% | +95.53% | 28.67B | |
| Weighted average by Cap. | -1.65% | -0.85% | +80.51% | +124.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.58B 8.82B 7.13B 6.51B 12.15B 836B 12.21B 84.53B 32.7B 427B 33.12B 32.4B 1,360B | 8B 9.3B 7.52B 6.87B 12.81B 882B 12.88B 89.15B 34.49B 451B 34.93B 34.17B 1,434B |
| Net income | 531M 617M 499M 456M 851M 58.54B 855M 5.92B 2.29B 29.92B 2.32B 2.27B 95.22B | 660M 767M 621M 566M 1.06B 72.74B 1.06B 7.35B 2.85B 37.18B 2.88B 2.82B 118B |
| Net Debt | 3.37B 3.91B 3.17B 2.89B 5.39B 371B 5.42B 37.52B 14.52B 190B 14.7B 14.38B 604B | 3.03B 3.53B 2.85B 2.6B 4.86B 335B 4.89B 33.82B 13.08B 171B 13.25B 12.96B 544B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-08 | €71.20 | -0.56% | 265,201 |
| 26-09-07 | €71.60 | -1.54% | 146,380 |
| 26-09-04 | €72.72 | -1.01% | 167,941 |
| 26-09-03 | €73.46 | +0.93% | 307,393 |
| 26-09-02 | €72.78 | +1.70% | 228,096 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
